A class action lawsuit has been initiated against Ardent Health, Inc., alleging the company issued materially false and misleading financial guidance in its third quarter 2025 results. According to the complaint, the company overstated revenue due to insufficient accounts receivable assessments following the implementation of a new accounting system. Additionally, the lawsuit contends that full-year 2025 EBITDA guidance was inflated by approximately $57.5 million, representing a 9.6% overstatement.
The alleged misstatements stem from two primary issues identified in the legal filing. First, the company failed to adequately evaluate collectibility of accounts receivable in connection with its recent accounting system transition. Second, management did not appropriately account for significant industry-wide cost pressures and elevated payer denials when establishing EBITDA projections for the full fiscal year.
Investors who acquired Ardent Health securities during the period from July 18, 2024, through November 12, 2025, are eligible to participate in the class action. The law firm Bronstein, Gewirtz & Grossman LLC is encouraging affected shareholders to evaluate their legal options regarding potential recovery.